Thursday, 18 April 2024

[the_ad_group id="2845"]

Business News

Filament Health Reports Q4 & Year-End Financials – TipRanks Financial Blog

LianBio reports Q3 EPS (20c), consensus (39c)

[the_ad id="21475"]


Filament Health Corp. (TSE:FH) has released an update.

Filament Health Corp., a natural psychedelic drug developer, reported Q4 and year-end 2023 financials and operational milestones, including the advancement of its lead drug, PEX010, for Phase 2 trials and a strategic shift away from a business combination to focus on more traditional financing. The company also achieved Health Canada approval for a Phase 2 trial of PEX010 for opioid use disorder and exported its product for clinical research in six countries. Despite operational progress, the company noted a cash position of $1.8 million and revenues of $2.1 million for the year.

For further insights into TSE:FH stock, check out TipRanks’ Stock Analysis page.

Click Here to Read the Full Original Article at TipRanks Financial Blog…


[the_ad id="21476"]